SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
Synthetic Biologics, Inc. (the Company) entered into an amendment
dated as of May 31, 2017 (the Amendment) to the employment
agreement with the Companys Chief Financial Officer, Steven A,
Shallcross, dated April 28, 2015, as amended on December 1, 2016
(the Employment Agreement). The Amendment amended the Employment
Agreement by, among other things, extending the term of the
Employment Agreement for an additional two years.
The information contained in this Item 1.01 regarding the
Amendment is qualified in its entirety by a copy of the Amendment
attached to this Current Report on Form 8-K as Exhibit 10.1 and
is incorporated herein by reference.
Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Item 1.01 of this Current Report on Form 8-K for a description of
the material terms of the Amendment, which terms are incorporated
herein by reference.
Item 9.01. Financial Statements and Exhibits.
The following exhibit is being filed as part of this Current
Report on Form 8-K.
Amendment to Employment Agreement, dated as of May 31, 2017,
by and between Steven A. Shallcross and Synthetic Biologics,
About SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN)
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU). SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Recent Trading Information
SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) closed its last trading session up +0.042 at 0.675 with 1,317,158 shares trading hands.